Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia
Keywords:
Enoxaparin, Covid-19, D-Dimer, Platelet, CRP
Abstract
Li Coagulopathy is a common predictor of mortality in COVID-19. Meanwhile, enoxaparin is an anticoagulant with anti-inflammatory, endothelial protection, and viral antagonist properties. Therefore, thromboprophylaxis with enoxaparin in COVID-19 is common in clinical settings. This study aims to assess enoxaparin's efficacy across different severity levels by examining its effect on primary outcomes comprising Length of stay (LOS), invasive mechanical ventilation, and mortality as well as secondary in the form of D-dimer, platelets, C-reactive protein (CRP), Neutrophil Lymphocyte Ratio (NLR), and Absolute Lymphocyte Count (ALC). During hospitalization, 269 patients received enoxaparin across varying severity levels comprising mild, moderate, and severe, while the Wilcoxon test was used to analyze the efficacy in each group. Additionally, the differences in patient characteristic profiles across the severity levels were determined using the Kruskal-Wallis test. The increase in mortality rate and the need for mechanical ventilation were directly proportional to the level of severity. D-dimer decreased from 1308.87 ng/ml to 979.83 ng/ml (p=<0,001) as well as from 1758.41 ng/ml to 1510.68 ng/ml (p=<0,001) in the mild and moderate levels respectively. The platelet increased from 225.65 to 369.39 x103/µl (p=<0,001) in mild and 256.77 to 398.97 x103/µl (p=<0,001) in moderate. Moreover, CRP improved in both mild 52.62 to 49.58 mg/l (p=0.031) and moderate 92.99 to 42.66 mg/l, (p=<0,001). Based on the results, enoxaparin effectively improves D-dimer, platelet, and CRP levels in mild and moderate but not in severe conditions, however, no effect was found on LOS, NLR, and ALC.
References
Abate, B. B., Kassie, A. M., Kassaw, M. W., Aragie, T. G., & Masresha, S. A. (2020). Sex difference in coronavirus disease (COVID-19): A systematic review and meta-analysis. BMJ Open, 10(10), 1–10. https://doi.org/10.1136/bmjopen-2020-040129
Al-Samkari, H., Gupta, S., Leaf, R. K., Wang, W., Rosovsky, R. P., Brenner, S. K., Hayek, S. S., Berlin, H., Kapoor, R., Shaefi, S., Melamed, M. L., Sutherland, A., Radbel, J., Green, A., Garibaldi, B. T., Srivastava, A., Leonberg-Yoo, A., Shehata, A. M., Flythe, J. E., … Leaf, D. E. (2021). Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with covid-19. Annals of Internal Medicine, 174(5), 622–632. https://doi.org/10.7326/M20-6739
Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., Di Maio, A., Faggian, B., Franceschetti, M. E., Massari, M., Salvaggio, M., & Natalini, G. (2020). Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27(April), 100562. https://doi.org/10.1016/j.eclinm.2020.100562
Arachchillage, D. R. J., & Laffan, M. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(5), 1233–1234. https://doi.org/10.1111/jth.14820
Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020). Severe Covid-19. New England Journal of Medicine, 383(25), 2451–2460. https://doi.org/10.1056/nejmcp2009575
Billett, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L. R., Lo, Y., Rahman, S., Gonzalez-Lugo, J. D., Kushnir, M., Barouqa, M., Golestaneh, L., & Bellin, E. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and Haemostasis, 120(12), 1691–1699. https://doi.org/10.1055/s-0040-1720978
Bwire, G. M. (2020). Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Comprehensive Clinical Medicine, 2(7), 874–876. https://doi.org/10.1007/s42399-020-00341-w
Cardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Snr, A. B., Snr, M. A., Iannuzzo, M., Sacco, C., Lodigiani, C., Fontanella, A., & Di Micco, P. (2021). Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: The FONDENOXAVID study. Journal of Blood Medicine, 12, 69–75. https://doi.org/10.2147/JBM.S285214
CDC. (2022). Covid-19. https://www.cdc.gov/coronavirus/2019-nCoV/index.html
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
Costanzo, L., Palumbo, F. P., Ardita, G., Antignani, P. L., Arosio, E., & Failla, G. (2020). Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8(5), 711–716. https://doi.org/10.1016/j.jvsv.2020.05.018
Dutt, T., Simcox, D., Downey, C., McLenaghan, D., King, C., Gautam, M., Lane, S., & Burhan, H. (2020). Thromboprophylaxis in COVID-19: Anti-FXa - The missing factor? American Journal of Respiratory and Critical Care Medicine, 202(3), 455–457. https://doi.org/10.1164/rccm.202005-1654LE
Elbeddini, A., Gerochi, R., & Elshahawi, A. (2020). Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy. Journal of Pharmaceutical Policy and Practice, 13(1), 1–9. https://doi.org/10.1186/s40545-020-00274-8
Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W., & Sheikh, T. (2003). Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice. Clinical Pharmacokinetics, 42(12), 1043–1057. https://doi.org/10.2165/00003088-200342120-00003
Gemmati, D., & Tisato, V. (2020). Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. 11(9), 1–17. https://doi.org/10.3390/genes11091044
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., Liu, F., Jiang, Y., Cheng, X., Zhu, C., & Xia, Y. (2020). Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes and Infections, 9(1), 1123–1130. https://doi.org/10.1080/22221751.2020.1770129
Hendren, N. S., De Lemos, J. A., Ayers, C., Das, S. R., Rao, A., Carter, S., Rosenblatt, A., Walchok, J., Omar, W., Khera, R., Hegde, A. A., Drazner, M. H., Neeland, I. J., & Grodin, J. L. (2021). Association of Body Mass Index and Age with Morbidity and Mortality in Patients Hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation, 135–144. https://doi.org/10.1161/CIRCULATIONAHA.120.051936
Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020). The unique characteristics of COVID-19 coagulopathy. Critical Care, 24(1), 4–11. https://doi.org/10.1186/s13054-020-03077-0
Jiménez-Soto, R., Aguilar-Soto, M., Rodríguez-Toledo, C. A., Camiro-Zúñiga, A., & Demichelis, R. (2021). The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19. Thrombosis Research, 202(December 2020), 14–16. https://doi.org/10.1016/j.thromres.2021.02.031
Jin, J., Bai, P., He, W., Wu, F., Liu, X., Han, D., & Liu, S. (2020). Gender Differences in Patients With COVID-19 : Focus on Severity and Mortality. Frontiers in Public Health, 8(152), 1–6. https://doi.org/10.3389/fpubh.2020.00152
Kamel, A. M., Sobhy, M., Magdy, N., Sabry, N., & Farid, S. (2021). Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Reviews in Medical Virology, 31(3). https://doi.org/10.1002/rmv.2180
Kluwer, W. (2022a). Enoxaparin : Drug Interactions. https://online.lexi.com/lco/action/interact/globalid/6105
Kluwer, W. (2022b). Enoxaparin (Lexi-Drugs). https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6820?cesid=6hYfqL8KCGL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Denoxaparin%26t%3Dname%26va%3Denoxaparin#phk
Kohansal Vajari, M., Shirin, M., Pourbagheri-Sigaroodi, A., Akbari, M. E., Abolghasemi, H., & Bashash, D. (2021). COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biology International, 45(9), 1832–1850. https://doi.org/10.1002/cbin.11623
Langer, F., Kluge, S., Klamroth, R., & Oldenburg, J. (2020). Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie, 40(3), 264–269. https://doi.org/10.1055/a-1178-3551
Li, Xiaochen, Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z., Renz, H., Liu, X., Xie, J., Xie, M., & Zhao, J. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146(1), 110–118. https://doi.org/10.1016/j.jaci.2020.04.006
Li, Xinyang, Zhong, X., Wang, Y., Zeng, X., Luo, T., & Liu, Q. (2021). Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS ONE, 16(5 May), 1–21. https://doi.org/10.1371/journal.pone.0250602
Liu, Y., Sun, W., Guo, Y., Chen, L., Zhang, L., Zhao, S., Long, D., & Yu, L. (2020). Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets, 31(4), 490–496. https://doi.org/10.1080/09537104.2020.1754383
Liverpool Drug Interactions Group. (2022). Interactions with experimental COVID-19 Antiviral Therapies. University of Liverpool, February, 1–6. www.covid19-druginteractions.org
Lopes, R. D., de Barros e Silva, P. G. M., Furtado, R. H. M., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., de Aveiro Morata, J., Ramacciotti, E., de Aquino Martins, P., de Oliveira, A. L., Nunes, V. S., Ritt, L. E. F., Rocha, A. T., Tramujas, L., Santos, S. V., Diaz, D. R. A., Viana, L. S., Melro, L. M. G., … Berwanger, O. (2021). Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomized, controlled trial. The Lancet, 397(10291), 2253–2263. https://doi.org/10.1016/S0140-6736(21)01203-4
Mennuni, M. G., Renda, G., Grisafi, L., Rognoni, A., Colombo, C., Lio, V., Foglietta, M., Petrilli, I., Pirisi, M., Spinoni, E., Azzolina, D., Hayden, E., Aimaretti, G., Avanzi, G. C., Bellan, M., Cantaluppi, V., Capponi, A., Castello, L. M., D’Ardes, D., … Patti, G. (2021). Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. Journal of Thrombosis and Thrombolysis, 52(3), 782–790. https://doi.org/10.1007/s11239-021-02401-x
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., & Wells, P. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest, 158(3), 1143–1163. https://doi.org/10.1016/j.chest.2020.05.559
Motta, J. K., Ogunnaike, R. O., Shah, R., Stroever, S., Cedeño, H. V., Thapa, S. K., Chronakos, J. J., Jimenez, E. J., Petrini, J., & Hegde, A. (2020). Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in Coronavirus Disease 2019. Critical Care Explorations, 2(12), e0309. https://doi.org/10.1097/cce.0000000000000309
Mousavi, S., Moradi, M., Khorshidahmad, T., & Motamedi, M. (2015). Anti-inflammatory effects of heparin and its derivatives: A systematic review. Advances in Pharmacological Sciences, 2015. https://doi.org/10.1155/2015/507151
Mukherjee, S., & Pahan, K. (2021). Is COVID-19 Gender-sensitive? Journal of Neuroimmune Pharmacology, 16, 38–47. https://doi.org/10.1007/s11481-020-09974-z
National Institutes of Health. (2021). Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). Nih, 2019, 1–243. https://www.covid19treatmentguidelines.nih.gov/
Nutescu, E. A., Burnett, A., Fanikos, J., Spinler, S., & Wittkowsky, A. (2016). Pharmacology of anticoagulants used in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 41(1), 15–31. https://doi.org/10.1007/s11239-015-1314-3
Ouassou, H., Kharchoufa, L., Bouhrim, M., Daoudi, N. E., Imtara, H., Bencheikh, N., ELbouzidi, A., & Bnouham, M. (2020). The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. Journal of Immunology Research, 2020, 1–7. https://doi.org/10.1155/2020/1357983
Pangarsa, E. A., Setiawan, B., Santosa, D., Naibaho, R. M., Rizky, D., Suyono, Tobing, M. L., & Suharti, C. (2020). Position paper from the Indonesian society of thrombosis and hemostasis (Inasth), Semarang chapter: Management of coagulopathy in COVID-19. Bali Medical Journal, 9(2), 482–488. https://doi.org/10.15562/bmj.v9i2.1841
Parasher, A. (2021). COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgraduate Medical Journal, 97(1147), 312–320. https://doi.org/10.1136/postgradmedj-2020-138577
Parisi, R., Costanzo, S., Di Castelnuovo, A., De Gaetano, G., Donati, M. B., & Iacoviello, L. (2021). Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Seminars in Thrombosis and Hemostasis, 47(4), 372–391. https://doi.org/10.1055/s-0041-1726034
PDPI, PERKI, PAPDI, PERDATIN, & IDAI. (2020). Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. In Pedoman Tatalaksana COVID-19. https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020
Peckham, H., de Gruijter, N. M., Raine, C., Radziszewska, A., Ciurtin, C., Wedderburn, L. R., Rosser, E. C., Webb, K., & Deakin, C. T. (2020). Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications, 11(1), 1–10. https://doi.org/10.1038/s41467-020-19741-6
Perepu, U. S., Chambers, I., Wahab, A., Ten Eyck, P., Wu, C., Dayal, S., Sutamtewagul, G., Bailey, S. R., Rosenstein, L. J., & Lentz, S. R. (2021). Standard prophylactic versus intermediate-dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. Journal of Thrombosis and Haemostasis, 19(9), 2225–2234. https://doi.org/10.1111/jth.15450
Pivonello, R., Auriemma, S., & Pivonello, C. (2021). Sex Disparities in COVID-19 Severity and Outcome : Are Men Weaker or Women Stronger ? Neuroendocrinology, 111, 1066–1085. https://doi.org/10.1159/000513346
Poudel, A., Poudel, Y., Adhikari, A., Aryal, B. B., Dangol, D., Bajracharya, T., Maharjan, A., & Gautam, R. (2021). D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS ONE, 16(8 August 2021), 1–13. https://doi.org/10.1371/journal.pone.0256744
Price, L. C., McCabe, C., Garfield, B., & Wort, S. J. (2020). Thrombosis and COVID-19 pneumonia: The clot thickens! European Respiratory Journal, 56(1). https://doi.org/10.1183/13993003.01608-2020
Rentsch, C. T., Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidwai-Khan, F., Skanderson, M., Brittain, E., King, J. T., Ho, Y. L., Eden, S., Kundu, S., Lann, M. F., Greevy, R. A., Ho, P. M., Heidenreich, P. A., Jacobson, D. A., Douglas, I. J., Tate, J. P., … Freiberg, M. S. (2021). Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. The BMJ, 372. https://doi.org/10.1136/bmj.n311
Rosovsky, R. P., Sanfilippo, K. M., Wang, T. F., Rajan, S. K., Shah, S., Martin, K. A., Ní Áinle, F., Huisman, M., Hunt, B. J., Kahn, S. R., Kevane, B., Lee, A. Y. Y., McLintock, C., & Baumann Kreuziger, L. (2020). Anticoagulation practice patterns in COVID-19: A global survey. Research and Practice in Thrombosis and Haemostasis, 4(6), 969–983. https://doi.org/10.1002/rth2.12414
Rusdiana, T., & Akbar, R. (2020). Perkembangan Terkini Terapi Antikoagulan Pada Pasien Covid-19 Bergejala Berat. Jurnal Sains Farmasi & Klinis, 7(3), 244. https://doi.org/10.25077/jsfk.7.3.244-250.2020
Selanno, Y., Widaningsih, Y., Esa, T., & Arif, M. (2021). Analysis of Neutrophil Lymphocyte Ratio and Absolute Lymphocyte Count as Predictors of Severity of COVID-19 Patients. Indonesian Journal of Clinical Pathology and Medical Laboratory, 27(2), 184–189. https://doi.org/10.24293/ijcpml.v27i2.1738
Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., Cheng, F., Liu, Y., Zhou, T., Deng, B., Vlodavsky, I., Li, J. P., & Zhang, Y. (2020). The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. Clinical and Translational Science, 13(6), 1087–1095. https://doi.org/10.1111/cts.12880
Simegn, A., Mesfin, D., Minuye, B., Ayanaw, B., & Muche, T. (2021). Sex and Gender Differences for Severity and Mortality from COVID-19 : Rapid Evidence Synthesis for the Implication of Health Equity in Access Policies. Health Science Journal, 15(8), 1–3.
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics, 87(4), 281–286. https://doi.org/10.1007/s12098-020-03263-6
Smits, S. L., De Lang, A., Van Den Brand, J. M. A., Leijten, L. M., Van Ijcken, W. F., Eijkemans, M. J. C., Van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., & Haagmans, B. L. (2010). Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathogens, 6(2). https://doi.org/10.1371/journal.ppat.1000756
Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., … Weitz, J. I. (2021). Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Internal Medicine, 181(12), 1612–1620. https://doi.org/10.1001/jamainternmed.2021.6203
Sunggoro, A. J., Purwanto, I., & Hasan, M. (2020). Trombosis pada corona virus disease (COVID-19). Jurnal Kedokteran Syiah Kuala, 20(3), 191–198. https://doi.org/10.24815/jks.v20i3.18689
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 18(5), 1094–1099. https://doi.org/10.1111/jth.14817
Vaughn, V. M., Yost, M., Abshire, C., Flanders, S. A., Paje, D., Grant, P., Kaatz, S., Kim, T., & Barnes, G. D. (2021). Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized with COVID-19. JAMA Network Open, 4(6), 1–13. https://doi.org/10.1001/jamanetworkopen.2021.11788
Vitiello, A., & Ferrara, F. (2021). Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-021-07251-6
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang, X., Zhang, H., Du, H., Ma, R., Nan, Y., & Zhang, T. (2021). Risk Factors for COVID-19 in Patients with Hypertension. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021. https://doi.org/10.1155/2021/5515941
WHO. (2022). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., Chen, X., Chen, S., Yu, K., Huang, Z., & Hu, B. (2020). D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. Journal of Intensive Care, 8(1), 1–11. https://doi.org/10.1186/s40560-020-00466-z
Zhan, H., Chen, H., Liu, C., Cheng, L., Yan, S., Li, H., & Li, Y. (2021). Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis, 27. https://doi.org/10.1177/10760296211010976
Zhang, J., Dong, X., Liu, G., & Gao, Y. (2022). Risk and Protective Factors for COVID ‑ 19 Morbidity , Severity , and Mortality. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-022-08921-5
Zhang, L., Feng, X., Zhang, D., Jiang, C., Mei, H., Wang, J., Zhang, C., Li, H., Xia, X., Kong, S., Liao, J., Jia, H., Pang, X., Song, Y., Tian, Y., Wang, B., Wu, C., Yuan, H., Zhang, Y., … Xie, M. (2020). Deep Vein Thrombosis in Hospitalized Patients with COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation, 142(2), 114–128. https://doi.org/10.1161/CIRCULATIONAHA.120.046702
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Zhou, X., Cheng, Z., Luo, L., Zhu, Y., Lin, W., Ming, Z., Chen, W., & Hu, Y. (2021). Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thrombosis Research, 201(November 2020), 23–29. https://doi.org/10.1016/j.thromres.2021.02.010
Zhu, Z., Cai, T., Fan, L., Lou, K., Hua, X., Huang, Z., & Gao, G. (2020). Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases, 95, 332–339. https://doi.org/10.1016/j.ijid.2020.04.041
Al-Samkari, H., Gupta, S., Leaf, R. K., Wang, W., Rosovsky, R. P., Brenner, S. K., Hayek, S. S., Berlin, H., Kapoor, R., Shaefi, S., Melamed, M. L., Sutherland, A., Radbel, J., Green, A., Garibaldi, B. T., Srivastava, A., Leonberg-Yoo, A., Shehata, A. M., Flythe, J. E., … Leaf, D. E. (2021). Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with covid-19. Annals of Internal Medicine, 174(5), 622–632. https://doi.org/10.7326/M20-6739
Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., Di Maio, A., Faggian, B., Franceschetti, M. E., Massari, M., Salvaggio, M., & Natalini, G. (2020). Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27(April), 100562. https://doi.org/10.1016/j.eclinm.2020.100562
Arachchillage, D. R. J., & Laffan, M. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(5), 1233–1234. https://doi.org/10.1111/jth.14820
Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020). Severe Covid-19. New England Journal of Medicine, 383(25), 2451–2460. https://doi.org/10.1056/nejmcp2009575
Billett, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L. R., Lo, Y., Rahman, S., Gonzalez-Lugo, J. D., Kushnir, M., Barouqa, M., Golestaneh, L., & Bellin, E. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and Haemostasis, 120(12), 1691–1699. https://doi.org/10.1055/s-0040-1720978
Bwire, G. M. (2020). Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Comprehensive Clinical Medicine, 2(7), 874–876. https://doi.org/10.1007/s42399-020-00341-w
Cardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Snr, A. B., Snr, M. A., Iannuzzo, M., Sacco, C., Lodigiani, C., Fontanella, A., & Di Micco, P. (2021). Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: The FONDENOXAVID study. Journal of Blood Medicine, 12, 69–75. https://doi.org/10.2147/JBM.S285214
CDC. (2022). Covid-19. https://www.cdc.gov/coronavirus/2019-nCoV/index.html
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
Costanzo, L., Palumbo, F. P., Ardita, G., Antignani, P. L., Arosio, E., & Failla, G. (2020). Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8(5), 711–716. https://doi.org/10.1016/j.jvsv.2020.05.018
Dutt, T., Simcox, D., Downey, C., McLenaghan, D., King, C., Gautam, M., Lane, S., & Burhan, H. (2020). Thromboprophylaxis in COVID-19: Anti-FXa - The missing factor? American Journal of Respiratory and Critical Care Medicine, 202(3), 455–457. https://doi.org/10.1164/rccm.202005-1654LE
Elbeddini, A., Gerochi, R., & Elshahawi, A. (2020). Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy. Journal of Pharmaceutical Policy and Practice, 13(1), 1–9. https://doi.org/10.1186/s40545-020-00274-8
Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W., & Sheikh, T. (2003). Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice. Clinical Pharmacokinetics, 42(12), 1043–1057. https://doi.org/10.2165/00003088-200342120-00003
Gemmati, D., & Tisato, V. (2020). Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. 11(9), 1–17. https://doi.org/10.3390/genes11091044
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., Liu, F., Jiang, Y., Cheng, X., Zhu, C., & Xia, Y. (2020). Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes and Infections, 9(1), 1123–1130. https://doi.org/10.1080/22221751.2020.1770129
Hendren, N. S., De Lemos, J. A., Ayers, C., Das, S. R., Rao, A., Carter, S., Rosenblatt, A., Walchok, J., Omar, W., Khera, R., Hegde, A. A., Drazner, M. H., Neeland, I. J., & Grodin, J. L. (2021). Association of Body Mass Index and Age with Morbidity and Mortality in Patients Hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation, 135–144. https://doi.org/10.1161/CIRCULATIONAHA.120.051936
Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020). The unique characteristics of COVID-19 coagulopathy. Critical Care, 24(1), 4–11. https://doi.org/10.1186/s13054-020-03077-0
Jiménez-Soto, R., Aguilar-Soto, M., Rodríguez-Toledo, C. A., Camiro-Zúñiga, A., & Demichelis, R. (2021). The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19. Thrombosis Research, 202(December 2020), 14–16. https://doi.org/10.1016/j.thromres.2021.02.031
Jin, J., Bai, P., He, W., Wu, F., Liu, X., Han, D., & Liu, S. (2020). Gender Differences in Patients With COVID-19 : Focus on Severity and Mortality. Frontiers in Public Health, 8(152), 1–6. https://doi.org/10.3389/fpubh.2020.00152
Kamel, A. M., Sobhy, M., Magdy, N., Sabry, N., & Farid, S. (2021). Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Reviews in Medical Virology, 31(3). https://doi.org/10.1002/rmv.2180
Kluwer, W. (2022a). Enoxaparin : Drug Interactions. https://online.lexi.com/lco/action/interact/globalid/6105
Kluwer, W. (2022b). Enoxaparin (Lexi-Drugs). https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6820?cesid=6hYfqL8KCGL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Denoxaparin%26t%3Dname%26va%3Denoxaparin#phk
Kohansal Vajari, M., Shirin, M., Pourbagheri-Sigaroodi, A., Akbari, M. E., Abolghasemi, H., & Bashash, D. (2021). COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biology International, 45(9), 1832–1850. https://doi.org/10.1002/cbin.11623
Langer, F., Kluge, S., Klamroth, R., & Oldenburg, J. (2020). Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie, 40(3), 264–269. https://doi.org/10.1055/a-1178-3551
Li, Xiaochen, Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z., Renz, H., Liu, X., Xie, J., Xie, M., & Zhao, J. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146(1), 110–118. https://doi.org/10.1016/j.jaci.2020.04.006
Li, Xinyang, Zhong, X., Wang, Y., Zeng, X., Luo, T., & Liu, Q. (2021). Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS ONE, 16(5 May), 1–21. https://doi.org/10.1371/journal.pone.0250602
Liu, Y., Sun, W., Guo, Y., Chen, L., Zhang, L., Zhao, S., Long, D., & Yu, L. (2020). Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets, 31(4), 490–496. https://doi.org/10.1080/09537104.2020.1754383
Liverpool Drug Interactions Group. (2022). Interactions with experimental COVID-19 Antiviral Therapies. University of Liverpool, February, 1–6. www.covid19-druginteractions.org
Lopes, R. D., de Barros e Silva, P. G. M., Furtado, R. H. M., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., de Aveiro Morata, J., Ramacciotti, E., de Aquino Martins, P., de Oliveira, A. L., Nunes, V. S., Ritt, L. E. F., Rocha, A. T., Tramujas, L., Santos, S. V., Diaz, D. R. A., Viana, L. S., Melro, L. M. G., … Berwanger, O. (2021). Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomized, controlled trial. The Lancet, 397(10291), 2253–2263. https://doi.org/10.1016/S0140-6736(21)01203-4
Mennuni, M. G., Renda, G., Grisafi, L., Rognoni, A., Colombo, C., Lio, V., Foglietta, M., Petrilli, I., Pirisi, M., Spinoni, E., Azzolina, D., Hayden, E., Aimaretti, G., Avanzi, G. C., Bellan, M., Cantaluppi, V., Capponi, A., Castello, L. M., D’Ardes, D., … Patti, G. (2021). Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. Journal of Thrombosis and Thrombolysis, 52(3), 782–790. https://doi.org/10.1007/s11239-021-02401-x
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., & Wells, P. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest, 158(3), 1143–1163. https://doi.org/10.1016/j.chest.2020.05.559
Motta, J. K., Ogunnaike, R. O., Shah, R., Stroever, S., Cedeño, H. V., Thapa, S. K., Chronakos, J. J., Jimenez, E. J., Petrini, J., & Hegde, A. (2020). Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in Coronavirus Disease 2019. Critical Care Explorations, 2(12), e0309. https://doi.org/10.1097/cce.0000000000000309
Mousavi, S., Moradi, M., Khorshidahmad, T., & Motamedi, M. (2015). Anti-inflammatory effects of heparin and its derivatives: A systematic review. Advances in Pharmacological Sciences, 2015. https://doi.org/10.1155/2015/507151
Mukherjee, S., & Pahan, K. (2021). Is COVID-19 Gender-sensitive? Journal of Neuroimmune Pharmacology, 16, 38–47. https://doi.org/10.1007/s11481-020-09974-z
National Institutes of Health. (2021). Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). Nih, 2019, 1–243. https://www.covid19treatmentguidelines.nih.gov/
Nutescu, E. A., Burnett, A., Fanikos, J., Spinler, S., & Wittkowsky, A. (2016). Pharmacology of anticoagulants used in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 41(1), 15–31. https://doi.org/10.1007/s11239-015-1314-3
Ouassou, H., Kharchoufa, L., Bouhrim, M., Daoudi, N. E., Imtara, H., Bencheikh, N., ELbouzidi, A., & Bnouham, M. (2020). The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. Journal of Immunology Research, 2020, 1–7. https://doi.org/10.1155/2020/1357983
Pangarsa, E. A., Setiawan, B., Santosa, D., Naibaho, R. M., Rizky, D., Suyono, Tobing, M. L., & Suharti, C. (2020). Position paper from the Indonesian society of thrombosis and hemostasis (Inasth), Semarang chapter: Management of coagulopathy in COVID-19. Bali Medical Journal, 9(2), 482–488. https://doi.org/10.15562/bmj.v9i2.1841
Parasher, A. (2021). COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgraduate Medical Journal, 97(1147), 312–320. https://doi.org/10.1136/postgradmedj-2020-138577
Parisi, R., Costanzo, S., Di Castelnuovo, A., De Gaetano, G., Donati, M. B., & Iacoviello, L. (2021). Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Seminars in Thrombosis and Hemostasis, 47(4), 372–391. https://doi.org/10.1055/s-0041-1726034
PDPI, PERKI, PAPDI, PERDATIN, & IDAI. (2020). Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. In Pedoman Tatalaksana COVID-19. https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020
Peckham, H., de Gruijter, N. M., Raine, C., Radziszewska, A., Ciurtin, C., Wedderburn, L. R., Rosser, E. C., Webb, K., & Deakin, C. T. (2020). Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications, 11(1), 1–10. https://doi.org/10.1038/s41467-020-19741-6
Perepu, U. S., Chambers, I., Wahab, A., Ten Eyck, P., Wu, C., Dayal, S., Sutamtewagul, G., Bailey, S. R., Rosenstein, L. J., & Lentz, S. R. (2021). Standard prophylactic versus intermediate-dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. Journal of Thrombosis and Haemostasis, 19(9), 2225–2234. https://doi.org/10.1111/jth.15450
Pivonello, R., Auriemma, S., & Pivonello, C. (2021). Sex Disparities in COVID-19 Severity and Outcome : Are Men Weaker or Women Stronger ? Neuroendocrinology, 111, 1066–1085. https://doi.org/10.1159/000513346
Poudel, A., Poudel, Y., Adhikari, A., Aryal, B. B., Dangol, D., Bajracharya, T., Maharjan, A., & Gautam, R. (2021). D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS ONE, 16(8 August 2021), 1–13. https://doi.org/10.1371/journal.pone.0256744
Price, L. C., McCabe, C., Garfield, B., & Wort, S. J. (2020). Thrombosis and COVID-19 pneumonia: The clot thickens! European Respiratory Journal, 56(1). https://doi.org/10.1183/13993003.01608-2020
Rentsch, C. T., Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidwai-Khan, F., Skanderson, M., Brittain, E., King, J. T., Ho, Y. L., Eden, S., Kundu, S., Lann, M. F., Greevy, R. A., Ho, P. M., Heidenreich, P. A., Jacobson, D. A., Douglas, I. J., Tate, J. P., … Freiberg, M. S. (2021). Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. The BMJ, 372. https://doi.org/10.1136/bmj.n311
Rosovsky, R. P., Sanfilippo, K. M., Wang, T. F., Rajan, S. K., Shah, S., Martin, K. A., Ní Áinle, F., Huisman, M., Hunt, B. J., Kahn, S. R., Kevane, B., Lee, A. Y. Y., McLintock, C., & Baumann Kreuziger, L. (2020). Anticoagulation practice patterns in COVID-19: A global survey. Research and Practice in Thrombosis and Haemostasis, 4(6), 969–983. https://doi.org/10.1002/rth2.12414
Rusdiana, T., & Akbar, R. (2020). Perkembangan Terkini Terapi Antikoagulan Pada Pasien Covid-19 Bergejala Berat. Jurnal Sains Farmasi & Klinis, 7(3), 244. https://doi.org/10.25077/jsfk.7.3.244-250.2020
Selanno, Y., Widaningsih, Y., Esa, T., & Arif, M. (2021). Analysis of Neutrophil Lymphocyte Ratio and Absolute Lymphocyte Count as Predictors of Severity of COVID-19 Patients. Indonesian Journal of Clinical Pathology and Medical Laboratory, 27(2), 184–189. https://doi.org/10.24293/ijcpml.v27i2.1738
Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., Cheng, F., Liu, Y., Zhou, T., Deng, B., Vlodavsky, I., Li, J. P., & Zhang, Y. (2020). The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. Clinical and Translational Science, 13(6), 1087–1095. https://doi.org/10.1111/cts.12880
Simegn, A., Mesfin, D., Minuye, B., Ayanaw, B., & Muche, T. (2021). Sex and Gender Differences for Severity and Mortality from COVID-19 : Rapid Evidence Synthesis for the Implication of Health Equity in Access Policies. Health Science Journal, 15(8), 1–3.
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics, 87(4), 281–286. https://doi.org/10.1007/s12098-020-03263-6
Smits, S. L., De Lang, A., Van Den Brand, J. M. A., Leijten, L. M., Van Ijcken, W. F., Eijkemans, M. J. C., Van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., & Haagmans, B. L. (2010). Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathogens, 6(2). https://doi.org/10.1371/journal.ppat.1000756
Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., … Weitz, J. I. (2021). Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Internal Medicine, 181(12), 1612–1620. https://doi.org/10.1001/jamainternmed.2021.6203
Sunggoro, A. J., Purwanto, I., & Hasan, M. (2020). Trombosis pada corona virus disease (COVID-19). Jurnal Kedokteran Syiah Kuala, 20(3), 191–198. https://doi.org/10.24815/jks.v20i3.18689
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 18(5), 1094–1099. https://doi.org/10.1111/jth.14817
Vaughn, V. M., Yost, M., Abshire, C., Flanders, S. A., Paje, D., Grant, P., Kaatz, S., Kim, T., & Barnes, G. D. (2021). Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized with COVID-19. JAMA Network Open, 4(6), 1–13. https://doi.org/10.1001/jamanetworkopen.2021.11788
Vitiello, A., & Ferrara, F. (2021). Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-021-07251-6
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang, X., Zhang, H., Du, H., Ma, R., Nan, Y., & Zhang, T. (2021). Risk Factors for COVID-19 in Patients with Hypertension. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021. https://doi.org/10.1155/2021/5515941
WHO. (2022). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., Chen, X., Chen, S., Yu, K., Huang, Z., & Hu, B. (2020). D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. Journal of Intensive Care, 8(1), 1–11. https://doi.org/10.1186/s40560-020-00466-z
Zhan, H., Chen, H., Liu, C., Cheng, L., Yan, S., Li, H., & Li, Y. (2021). Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis, 27. https://doi.org/10.1177/10760296211010976
Zhang, J., Dong, X., Liu, G., & Gao, Y. (2022). Risk and Protective Factors for COVID ‑ 19 Morbidity , Severity , and Mortality. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-022-08921-5
Zhang, L., Feng, X., Zhang, D., Jiang, C., Mei, H., Wang, J., Zhang, C., Li, H., Xia, X., Kong, S., Liao, J., Jia, H., Pang, X., Song, Y., Tian, Y., Wang, B., Wu, C., Yuan, H., Zhang, Y., … Xie, M. (2020). Deep Vein Thrombosis in Hospitalized Patients with COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation, 142(2), 114–128. https://doi.org/10.1161/CIRCULATIONAHA.120.046702
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Zhou, X., Cheng, Z., Luo, L., Zhu, Y., Lin, W., Ming, Z., Chen, W., & Hu, Y. (2021). Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thrombosis Research, 201(November 2020), 23–29. https://doi.org/10.1016/j.thromres.2021.02.010
Zhu, Z., Cai, T., Fan, L., Lou, K., Hua, X., Huang, Z., & Gao, G. (2020). Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases, 95, 332–339. https://doi.org/10.1016/j.ijid.2020.04.041
Published
2022-09-28
How to Cite
Suprapti, B., Debora, L., Kusumawati, D., Dery PS, A., T, G. N., Arini, M. N., & Aryanti, L. D. (2022). Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia. Indonesian Journal of Pharmacy, 33(3), 381-393. https://doi.org/10.22146/ijp.4133
Issue
Section
Review Article
